Are Wegovy and Ozempic worth the cost? What economists found

If you have priced Wegovy or Ozempic without insurance, you already know the shock: often more than $1,000 a month. A 2026 review of the economics asked a blunt question - at that price, are these drugs actually worth it? The answer health economists reached is uncomfortable, and it explains a lot about why coverage is so patchy.

TL;DR

A 2026 meta-analysis of 9 economic studies found that semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) are not cost-effective for obesity at current US prices when compared with cheaper options like lifestyle programs or older weight-loss pills. They cleared the standard value-for-money bar only against no treatment at all, and only over more than 10 years. The drugs work. What the study flags is the price, not the effectiveness - and Novo Nordisk's planned 2027 price cut could change the math.

What the study actually looked at

The analysis, published in Diabetes, Obesity and Metabolism in 2026, pooled 9 separate economic evaluations that together ran 23 comparisons. Almost all came from the United States, with one from Switzerland. Every study modeled adults, and in some cases adolescents, with obesity, a body mass index of 30 or higher, and without diabetes. That is the classic weight-loss patient most people picture.

Two drugs were in the frame: semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes, and liraglutide, sold as Saxenda. Tirzepatide (Mounjaro, Zepbound) was not evaluated, so nothing here tells you whether Lilly's drug is a better deal. That gap matters, because tirzepatide now produces more weight loss than semaglutide in head-to-head trials.

Cost-effectiveness is not the same as "expensive" or "cheap." It is a value-for-money calculation: how much extra you pay for the extra health you get. Economists measure that health in quality-adjusted life years, or QALYs, where one QALY is roughly one year lived in full health. In the US, a treatment is usually judged good value if it costs less than about $100,000 for each QALY it adds. That $100,000 threshold is the bar every drug in this review was measured against.

What the study found

Measured against that bar, semaglutide and liraglutide fell short in most comparisons. Here is how the verdict broke down by what the drugs were compared with.

Compared with	Verdict for semaglutide and liraglutide
Lifestyle programs (diet, coaching)	Not cost-effective
Phentermine-topiramate (older weight-loss pill)	Not cost-effective
Naltrexone-bupropion (older weight-loss pill)	Not cost-effective
No treatment at all	Cost-effective only over more than 10 years

Read that bottom row carefully, because it is the whole story. The only scenario where these drugs looked like good value was against doing nothing, and even then only if you assume someone stays on the drug for more than a decade. Against any of the cheaper active alternatives, the extra weight loss did not justify the extra cost at the $100,000 threshold. The authors were clear about why: the price of the GLP-1 drug was consistently the single biggest factor deciding whether it passed or failed.

What "not cost-effective" actually means

This is the part that gets misread, so let me be blunt. "Not cost-effective" does not mean the drug does not work. Semaglutide reliably produces around 15% weight loss, and the higher-dose Wegovy version reaches about 20%. Nobody in this study disputed that.

Cost-effectiveness is a judgment about price versus benefit at a chosen threshold, not about whether the medicine does its job. A drug can be highly effective and still be rated poor value simply because it costs far more than a cheaper option that delivers a good chunk of the same benefit. That is exactly what the review found. The older weight-loss pills are much cheaper, and while they produce less weight loss, they produce enough that the far pricier GLP-1 drug struggles to justify the gap on paper. It is the same logic an insurer uses. This is a statement about the price tag, not about the science.

Why this matters for your insurance and access

These analyses are not academic trivia. They are close to the exact math that insurers, employers, and state Medicaid programs use to decide what they will pay for. When a respected economic review keeps landing on "not cost-effective at this price," it becomes the ammunition for a coverage denial.

You are already seeing the fallout. Only a handful of state Medicaid programs still cover GLP-1 drugs for obesity, and several have pulled back. Many employers have added prior-authorization hoops or dropped weight-loss coverage entirely. If you have ever been told your plan covers Ozempic for diabetes but not Wegovy for weight, this cost-versus-benefit gap is a big reason why. The drug is the same molecule. The price-versus-benefit case is what your plan is arguing about.

How 2027 price cuts and generics could change the math

Here is the hopeful part, and the reason this verdict may not hold. Every one of these studies used current or recent US prices, and the authors named price as the key driver. Lower the price, and the whole calculation shifts.

Two things are moving. Novo Nordisk has announced it will cut the US price of Wegovy to around $675 a month starting in January 2027, with a smaller cut to Ozempic. And generic competition is opening up: regulators have laid out the approval pathway, and the first applications for generic versions of related GLP-1 drugs have been accepted. When prices fall by a third to a half, a drug that failed the $100,000 test at $1,300 a month can start to pass it. Early findings like this one are a snapshot of today's prices, not a permanent ruling.

Compounded semaglutide has been a cheaper workaround for many people, though its future is uncertain while the FDA reviews whether to restrict it. We cover where that stands in our explainer on what the compounded GLP-1 proposal means for patients.

Getting your money's worth if you do take a GLP-1

Whatever your plan decides, if you are paying real money for a GLP-1 drug, the goal is to protect that spending. The fastest way to waste it is to lose the weight and then regain it. Research shows people regain roughly 0.8 kg a month after stopping, drifting back toward their starting weight within about 18 months. Every regained pound erases part of what you paid for. Our piece on what happens when you stop taking Ozempic or Wegovy lays out that pattern.

Two things protect the value of the money you spend. The first is staying on the drug long enough, at a dose you can tolerate, which usually means managing side effects rather than quitting. The second is protecting your body while the weight comes off, and this is where a lot of value quietly leaks away. Up to 40% of the weight lost on a GLP-1 can be muscle, and a shrinking appetite makes protein and key nutrients hard to reach from food alone.

That nutrient gap is the problem GLP-1 Shield is built to close. Losing weight while losing muscle and running low on vitamin B12, vitamin D, or iron is a poor return on an expensive drug. The right GLP-1 supplements and a real protein target help you keep the lean mass and energy that make the results worth paying for. Our guide to muscle loss and protein intake covers the specifics.

Before you commit to paying out of pocket, a few questions are worth asking your prescriber or insurer:

1. Does my plan cover this drug for my specific diagnosis? Coverage often differs between the diabetes and obesity versions of the same molecule.
2. Is there a cheaper alternative worth trying first? Older weight-loss medicines cost far less and may be enough for your goal.
3. What is the manufacturer's savings or copay program? These can cut the monthly cost sharply for eligible patients.
4. What is my plan for keeping the weight off? The cost only pays off if the results last.

What to remember

• A 2026 review of 9 economic studies rated semaglutide and liraglutide not cost-effective for obesity at current US prices versus cheaper options.
• The drugs cleared the value bar only against no treatment, and only over more than 10 years.
• "Not cost-effective" is a verdict about price, not about whether the drugs work - they still produce 15% to 20% weight loss.
• Insurers and Medicaid use this same math, which is why coverage is patchy and often limited to diabetes.
• Announced 2027 price cuts and coming generics could flip the verdict.

This article is general information, not medical or financial advice. GLP-1 medications are prescription-only, and decisions about starting, switching, or stopping them, and about what your insurance will cover, belong with your prescriber and your plan.

In one sentence: Wegovy and Ozempic work, but at today's US prices health economists say you are paying more than the extra weight loss is worth compared with cheaper options, a gap that lower prices in 2027 could close.

Frequently asked questions

Are Ozempic and Wegovy worth the money?

Clinically they work, producing about 15% to 20% weight loss, but a 2026 review in Diabetes, Obesity and Metabolism found semaglutide is not cost-effective at current US prices when compared with cheaper options like lifestyle programs or older weight-loss pills. Whether it is worth it for you depends on your budget, your insurance, and how long you can stay on it. Announced 2027 price cuts may improve the value.

Why do insurers say GLP-1 drugs are not cost-effective?

Because cost-effectiveness compares price against health gained, usually at a threshold near $100,000 per quality-adjusted life year. The 2026 meta-analysis found that at roughly $1,000 or more a month, semaglutide and liraglutide cost more than that threshold allows when weighed against cheaper alternatives. The drug's price, not its effectiveness, was the deciding factor, which is why many plans limit or deny obesity coverage.

Will Ozempic and Wegovy get cheaper in 2027?

Novo Nordisk has announced it will cut the US price of Wegovy to around $675 a month starting January 2027, with a smaller reduction for Ozempic. Generic competition is also opening up, with the first generic applications for related drugs accepted by regulators. Lower prices would directly improve the cost-effectiveness verdict, since price was named as the single biggest driver.

Does this study mean GLP-1 drugs do not work?

No. "Not cost-effective" is a judgment about price versus benefit, not about whether the medicine works. Semaglutide reliably produces around 15% weight loss and the high-dose version about 20%, and the study did not dispute that. The finding is that at current US prices the extra cost outweighs the extra benefit compared with cheaper options, not that the drugs are ineffective.